Broad spectrum gastrointestinal anthelmintic indicated for the treatment of: Enterobius vermicularis (threadworm/pinworm) Oxyuris vermicularis Trichuris trichuria (whipworm) Ascaris lumbricoides (large roundworm) Ancylostoma duodenale (common hookworm) Necator americanus (American hookworm) There is no evidence that Vermox is effective in the treatment of cysticercosis.
For the treatment of Trichuris trichuria (whipworm), Enterobius vermicularis (pinworm or threadworm), Ascaris lumbricoides (roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed gastrointestinal infestations. There is no evidence that Vermox Tablets are effective in the treatment of cysticercosis.
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...
Ariad Pharmaceuticals, Inc. announced that it is temporarily suspending the marketing and commercial distribution of Iclusig (ponatinib), a treatment for...
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
The FDA has approved AbbVie's Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with...
Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that MTPC obtained the regulatory approval of Radicut Oral Suspension 2.1% (generic name: edaravone) for the treatment of patients with amyotrophic lateral sclerosis (ALS) from the Ministry of Health, Labour and Welfare on December 23, 2022.